Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 181-189 , March 2003

Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes

  • Hirohito Kazama

      Affiliations

    • Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
    • Corresponding Author InformationCorresponding author. Present address: Department of Internal Medicine, Kikkoman General Hospital, 100 Miyazaki, Noda-city, Chiba 278-0005, Japan. Tel.: +81-47-12-35911; fax: +81-47-12-35920
    • ,
  • S Usui

      Affiliations

    • Department of Biochemistry and Biophysics, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan
    • ,
  • M Okazaki

      Affiliations

    • Laboratory of Chemistry, College of Liberal Arts and Sciences, Tokyo Medical and Dental University, 2-8-30 Kohnodai, Ichikawa-shi, Chiba 272-0827, Japan
    • ,
  • T Hosoi

      Affiliations

    • Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
    • ,
  • H Ito

      Affiliations

    • Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan
    • ,
  • H Orimo

      Affiliations

    • Department of Endocrinology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan

Received 25 February 2002 ,Revised 11 September 2002 ,Accepted 1 October 2002.

References 

  1. Ginsberg HN. Lipoprotein physiology in non-diabetic and diabetic states: relationship to atherosclerosis. Diabetes Care. 1991;14:839–855
  2. Austin MA, Mykkanen L, Kuusisto J, et al.  Prospective study of small LDLs as a risk factor for type 2 diabetes in elderly men and women. Circulation. 1995;92:1770–1778
  3. Selby J, Austin M, Newman B, Mayer E, Krauss RM. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993;381:381–387
  4. Watanabe N, Taniguchi T, Taketoh H, et al.  Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999;22:152–156
  5. McNamara JR, Boquist S, Tang R, Bond JM, de Faire U, Hamsten A. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229–237
  6. Takeichi S, Nakajima Y, Osawa M, Yukawa M, Saito T, Seto et al Y. The possible role of remnant-like particles as risk factor for sudden cardiac death. Int. J. Legal Med. 1997;110:213–219
  7. Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HESJ, Donker AJM, Heine RJ. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 2000;16:82–87
  8. Nagai T, Tomizawa T, Nakajima K, Masatomo M. Effects of bezafibrate and pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 2000;7:91–96
  9. Kulkarni KR, Garder DW, Jones MK, Segrest JP. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J. Lipid Res. 1995;36:2291–2302
  10. Krauss R, Burke D. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 1982;23:97–104
  11. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta. 1981;665:408–419
  12. Okazaki M, Usui S, Hosaki S. Analysis of plasma lipoproteins by gel permeation chromatography. In:  Rifai N,  Warnick GR,  Dominiczak MH editor. Handbook of Lipoprotein Testing. second ed.. Washington, DC: AACC Press; 2000;p. 647–669
  13. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias . Guideline for diagnosis and treatment of hyperlipidemias in adults. J. Japanese Atheroscler. Soc. 1997;25:1–34
  14. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin. Chem. 1998;44:1224–1232
  15. Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss RM. Low-density-lipoprotein subclass patterns and risk of myocardial infarction. J. Am. Med. Assoc. 1988;260:1917–1921
  16. Ruotolo G, Ericsson CG, Tettamanti C, et al.  Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol. 1998;32:1648–1656
  17. Homma Y, Ozawa H, Kobayashi T, et al.  Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis. 1994;106:191–201
  18. Franceschini G, Cassinotti M, Vecchio G, et al.  Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler. Thromb. 1994;14:1569–1575
  19. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis. 1998;141:87–98
  20. Johanson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb. 1991;11:174–182
  21. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl. J. Med. 1991;325:377–381
  22. Cheung MC, Austin MA, Moulin P, Anitra CW, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993;102:107–119

PII: S0168-8227(02)00243-7

Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 181-189 , March 2003

Article Tools

* Image Usage & Resolution